About Shenzhen Sungening Biological Co., Ltd

Sungening Biotechnology Co., Ltd. is a globally renowned pharmaceutical innovation enterprise that focuses on the research and development of drugs for metabolic diseases, anti-tumor and anti infective fields, starting from drugs that do not meet clinical needs.

About Shenzhen Sungening Biological Co., Ltd

Sungening Biotechnology Co., Ltd. is a globally renowned pharmaceutical innovation enterprise that focuses on the research and development of drugs for metabolic diseases, anti-tumor and anti infective fields, starting from drugs that do not meet clinical needs.

Company Overview

Shenzhen Sungening Biological Co., Ltd, shorted as Sungening, established in 2021, has risen rapidly amidst the wave of innovative drug research and development, deploying several innovative drug pipelines in fields such as anti-infective, metabolic diseases, and oncology, with a particular focus on groundbreaking advancements in anti-fungal infections and deep exploration of oral cyclic peptide technology. Our aim is to address the urgent clinical need for anti-fungal treatment options, striving to make oral cyclic peptide drugs the first choice for patients, simplifying treatment processes, reducing psychological burdens, and enhancing patient compliance.

 

Sungening has achieved notable milestones in the cutting-edge fields of anti-fungal infections and oral cyclic peptides. One of our innovative drug pipelines targeting anti-fungal infections has successfully obtained IND (investigational new drug), marking a substantial step into clinical trials in this field. Two more pipelines are undergoing intense clinical application processes, demonstrating the company's robust R&D execution and project advancement capabilities. Furthermore, two pipelines have progressed to the PCC (Pre-Clinical Candidate) stage, foreshadowing the potential for more innovative breakthroughs to benefit a broader patient population in the future.

For better presentation, please browse vertically on the mobile end